Picture of Olympus logo

7733 Olympus News Story

0.000.00%
jp flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

RCS - Osler Diagnostics Ld - Osler Diagnostics - Board Appointments

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220321:nRSU3650Fa&default-theme=true

RNS Number : 3650F  Osler Diagnostics Limited  21 March 2022

Osler Diagnostics Appoints Chris Smith as Chairman of the Board

and David Berry as a Non-Executive Director

 

Oxford, UK - 21 March 2022: Osler Diagnostics ('Osler' or the 'Company') is
pleased to announce the appointment of Chris Smith as Chairman of the Board of
Directors and David Berry as a Non-Executive Director, with immediate effect.

 

Chris Smith is the CEO of Ortho Clinical Diagnostics ('Ortho'), a leading
global diagnostic company. In December 2021, Quidel Corporation announced that
it would acquire Ortho for around $6 billion. Chris also serves on the boards
of several companies including Nyxoah and Akouos.

 

Prior to joining Ortho, Chris was CEO of Cochlear, a global medical device
company headquartered in Australia. Under his leadership, Cochlear reached
annual sales in excess of AU$1 billion while the market cap of the company
more than doubled. Prior to taking over as CEO, Chris served as the president
of Cochlear Americas, more than quadrupling revenue during his tenure.

 

Prior to Cochlear, Chris held several senior executive roles, including CEO in
residence for Warburg Pincus and global group president of Gyrus Group Plc., a
surgical products company. In addition, early in his career he held roles in
Abbott, Cardinal, Prism and KCI. Chris has also served as a senior external
advisor for McKinsey & Co., and EQT Partners. Chris holds a Bachelor of
Science degree from Texas A&M University.

 

David Berry is Founder and CEO of Valo Health, and since 2005 has worked at
Flagship Pioneering, where he is a General Partner, focused on conceiving,
creating, resourcing, and launching groundbreaking companies. David has
co-founded more than 20 companies across life sciences and sustainability.

 

David has been broadly recognised as a world-leading innovator: elected as a
Young Global Leader by the World Economic Forum, named as Innovator of the
Year by MIT Technology Review from amongst its annual TR35 list, and
selected as one of 12 Innovators Reshaping Reality by the U.S. State
Department, alongside pioneers such as Tim Berners-Lee. He holds over 200
patents and patent applications, and he and his companies have been awarded
with more than 150 additional awards and honours. David also serves on the
United Nations Sustainable Development Solutions Network (UN SDSN), where he
was a Founding Leadership Council Member.

 

David received his M.D. from Harvard Medical School and his Ph.D. from MIT in
biological engineering, through the Health Sciences and Technology program,
completing the fastest dual degree in the modern history of the program.

 

Connor Campbell, co-founder and CEO of Osler, commented: "We are pleased to
welcome Chris and David to Osler's Board. Their expertise, and proven track
records in driving value creation across businesses, will be critical in
helping Osler in our next phase of growth."

 

Chris Smith, Chairman of Osler, commented: "I am excited to take on the role
of Chairman at such a pivotal time for the Company. The Company's Osler Origin
platform - a 'portable lab' that can provide lab-quality diagnostics to
anyone, anywhere, at any time - is positioned to be a game changing
technology, especially as more and more patients and clinical customers focus
on decentralised testing. I'm looking forward to partnering with Connor and
the entire Osler team."

 

David Berry, Non-Executive Director of Osler, added: "I firmly believe we are
at the precipice of a new era in healthcare. The fundamental need is
diagnostics that enable rapid, high-fidelity decision making but meeting the
patient where they are. This is the promise of Osler, I look forward to
helping Osler make this a reality."

 

 

 

About Osler

Osler is a UK-based diagnostics company whose purpose is to enable anyone,
anywhere, to access, understand, and act on their health, to live healthier,
happier, and longer lives.

 

Osler has developed the Osler Origin - a 'portable lab' that can provide
lab-quality diagnostics to anyone, anywhere, at any time. The Osler Origin
will offer a wide portfolio of diagnostic tests and serve all major healthcare
settings, globally.

 

Osler was formed out of the University of Oxford in 2017, following decades of
research from the same department that invented the portable electrochemical
blood glucose sensor.

 

The Company is headquartered in Oxford, UK, employs approximately 100 staff
and is backed by leading investors.

 

For more information, please visit www.oslerdiagnostics.com
(http://www.oslerdiagnostics.com)

 

Contacts

Consilium Strategic Communications
 Osler Diagnostics

                                                                Mary-Jane Elliott
 media@oslerdiagnostics.com (mailto:media@oslerdiagnostics.com)

                                                                + 44 7739 788 014

                                                                  osler@consilium-comms.com (mailto:osler@consilium-comms.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPUAPWUPPPUU

Recent news on Olympus

See all news